Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Nanozyme-catalysed CRISPR assay for preamplification-free detection of non-coding RNAs

Nanozyme-catalysed CRISPR assay for preamplification-free detection of non-coding RNAs

Thumbnail Image
Download
Name

2022-NatNano-accepted.pdf

Description
Accepted version
Size

805.74 KB

Format

Adobe PDF

Checksum (MD5)

7e4c62eecf79f85e2df7f79197007a93

sword-2023-02-09T14:17:02.original.xml (130 B)
Original SWORD entry document
Author(s)
Broto, Marta
•
Kaminski, Michael M
•
Adrianus, Christopher
•
Kim, Nayoung
•
Greensmith, Robert
•
Dissanayake-Perera, Schan
•
Schubert, Alexander J
•
Tan, Xiao
•
Kim, Hyemin
•
Dighe, Anand S
more
Date Issued
2022
Journal
Nature Nanotechnology
Publisher
Springer Science and Business Media LLC
Citation
Broto, Marta, Kaminski, Michael M, Adrianus, Christopher, Kim, Nayoung, Greensmith, Robert et al. 2022. "Nanozyme-catalysed CRISPR assay for preamplification-free detection of non-coding RNAs." Nature Nanotechnology, 17 (10).
Version
Author's final manuscript
Abstract
CRISPR-based diagnostics enable specific sensing of DNA and RNA biomarkers associated with human diseases. This is achieved through the binding of guide RNAs to a complementary sequence that activates Cas enzymes to cleave reporter molecules. Currently, most CRISPR-based diagnostics rely on target preamplification to reach sufficient sensitivity for clinical applications. This limits quantification capability and adds complexity to the reaction chemistry. Here we show the combination of a CRISPR-Cas-based reaction with a nanozyme-linked immunosorbent assay, which allows for the quantitative and colorimetric readout of Cas13-mediated RNA detection through catalytic metallic nanoparticles at room temperature (CrisprZyme). We demonstrate that CrisprZyme is easily adaptable to a lateral-flow-based readout and different Cas enzymes and enables the sensing of non-coding RNAs including microRNAs, long non-coding RNAs and circular RNAs. We utilize this platform to identify patients with acute myocardial infarction and to monitor cellular differentiation in vitro and in tissue biopsies from prostate cancer patients. We anticipate that CrisprZyme will serve as a universally applicable signal catalyst for CRISPR-based diagnostics, which will expand the spectrum of targets for preamplification-free, quantitative detection.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/147986
DOI of Published Version
https://doi.org/10.1038/S41565-022-01179-0
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.